Actions for A treatment planning comparison of BPA- or BSH-based BNCT of malignant gliomas [electronic resource].

Email RIS file
Bookmark
Report an Issue

A treatment planning comparison of BPA- or BSH-based BNCT of malignant gliomas [electronic resource].

Published
Washington, D.C. : United States. Dept. of Energy. Office of Energy Research, 1996.
Oak Ridge, Tenn. : Distributed by the Office of Scientific and Technical Information, U.S. Dept. of Energy.
Physical Description
11 pages : digital, PDF file
Additional Creators
Brookhaven National Laboratory, United States. Department of Energy. Office of Energy Research, and United States. Department of Energy. Office of Scientific and Technical Information
Access Online

Availability

I Want It
I Want It

Finding items...

Restrictions on Access
Free-to-read Unrestricted online access
Summary
Accurate delivery of the prescribed dose during clinical BNCT requires knowledge (or reasonably valid assumptions) about the boron concentrations in tumor and normal tissues. For conversion of physical dose (Gy) into photon-equivalent dose (Gy-Eq), relative biological effectiveness (RBE) and/or compound-adjusted biological effectiveness (CBE) factors are required for each tissue. The BNCT treatment planning software requires input of the following values: the boron concentration in blood and tumor, RBEs in brain, tumor and skin for the high-LET beam components, the CBE factors for brain, tumor, and skin, and the RBE for the gamma component.
Report Numbers
E 1.99:bnl--64626
E 1.99: conf-9609293--
conf-9609293--
bnl--64626
Subject(s)
Other Subject(s)
Note
Published through SciTech Connect.
12/31/1996.
"bnl--64626"
" conf-9609293--"
"DE97008895"
7. international symposium on neutron capture therapy for cancer, Zurich (Switzerland), 4-7 Sep 1996.
Chanana, A.D.; Coderre, J.A.; Capala, J.
Funding Information
AC02-76CH00016
View MARC record | catkey: 14987686